| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Change in fair value of upfront purchase price liability | - | - | -4,500 | - |
| Total other income (expenses) | 1,137,085 | 36,644 | 86,182 | 146,711 |
| Net loss before provision for income taxes | -808,502 | -1,377,276 | -851,764 | -1,513,010 |
| Income taxes | - | 0 | - | - |
| Net loss | -808,502 | -1,377,276 | -851,764 | -1,513,010 |
| Non-controlling interest | -1,109,371 | -143,858 | 10,357 | 25,623 |
| Net loss attributable to biocorrx inc. | - | - | - | -1,487,387 |
| Net loss attributible to biocorrx, inc | -1,917,873 | -1,233,418 | -841,407 | - |
| Basic & diluted eps | - | - | - | -0.14 |
| Weighted average number of common shares outstanding, basic and diluted | - | 17,011,680 | - | - |
| Net loss per common share, basic and diluted | -0.11 | -0.07 | - | - |
| Weighted average number of common shares outstanding, basic and diluted | 18,162,783 | - | 3,552,262 | - |
BioCorRx Inc. (BICX)
BioCorRx Inc. (BICX)